Skip to main navigation
Skip to search
Skip to main content
Maastricht University Home
Support & FAQ
Link opens in a new tab
Search content at Maastricht University
Home
Researchers
Publications
Activities
Press/Media
Prizes
Organisations
Dataset/Software
Projects
Medications for insomnia
Lorenz Van der Linden
,
Kristien Coteur
, Jos Tournoy
Research output
:
Chapter in Book/Report/Conference proceeding
›
Chapter
›
Academic
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Medications for insomnia'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Access Barriers
50%
Active Patient Involvement
50%
Adverse Outcomes
50%
Balance Intervention
50%
Benzodiazepine Receptor Agonists
50%
Chronic Insomnia
50%
Cognitive Behavioral Therapy for Insomnia (CBT-I)
50%
Cognitive Decline
50%
Concentration Difficulties
50%
Daily Functioning
50%
Hypnotic Agent
50%
Insomnia
100%
Later Life
50%
Limited Access
50%
Long-term Benefit
50%
Memory Difficulties
50%
Mirtazapine
50%
Off-label Use
100%
Older Adults
100%
Pharmacological Therapy
50%
Placebo-controlled Trial
50%
Practical Barriers
50%
Prolonged Use
50%
Psychiatric Comorbidity
50%
Trazodone
50%
Treatment Decisions
50%
Treatment Lines
50%
Medicine and Dentistry
Adverse Outcome
100%
Benzodiazepine Receptor Stimulating Agent
100%
Cognitive Behavioral Therapy
100%
Cognitive Decline
100%
Comorbidity
100%
Drug Therapy
100%
Hypnotic
100%
Mirtazapine
100%
Off-Label Use
100%
Patient Participation
100%
Placebo
100%
Trazodone
100%
INIS
adults
100%
balances
50%
barriers
50%
concentration
50%
data
50%
demand
50%
drugs
50%
interventions
50%
management
50%
patients
100%
psychological behavior
50%
range
50%
receptors
50%
safety
50%
sleep
50%
therapy
100%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Outcome
100%
Benzodiazepine Receptor Stimulating Agent
100%
Comorbidity
100%
Hypnotic
100%
Mirtazapine
100%
Off-Label Use
100%
Pharmacotherapy
100%
Placebo
100%
Trazodone
100%
Neuroscience
Benzodiazepine Receptor
50%
Cognitive Behavioral Therapy
50%
Cognitive Decline
50%
Comorbidity
50%
Drug Therapy
50%
Hypnotic
50%
Mirtazapine
50%
Older Adults
100%
Placebo
50%
Receptor Agonists
50%
Trazodone
50%